Genomic analysis and therapeutic efficacy evaluation of bacteriophage PK2420 for pneumonia caused by hypervirulent Klebsiella pneumoniae (K20 serotype)
mSystems · 2025
DOI: 10.1128/msystems.01632-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSystems, 2025. Verfasst von Jinfeng Chen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Capital Institute of Pediatrics-Peking University Teaching Hospital, Beijing, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Klebsiella Infections, Phage Therapy, Bacteriophages. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hypervirulent Klebsiella pneumoniae (hvKp) strains are increasingly recognized for their aggressive nature, which leads to severe clinical outcomes. The emergence of multidrug-resistant strains constitutes a substantial challenge for clinical management. Phage therapy offers a potential solution to the antibiotic resistance crisis. A multidrug-resistant hvKp strain, K2420 (K20 serotype), was used to isolate bacteriophages from hospital sewage. Phage morphology, biological properties, and genome characteristics were analyzed using transmission electron microscopy, plaque assays, and whole-genome sequencing. Therapeutic safety and efficacy were assessed in an acute pneumonia murine model induced by intratracheal injection of K2420. Assessment parameters included bacterial load, phage titer, body temperature, cytokine levels, histopathological findings, and other relevant indicators. Phage PK2420, a member of the Autographiviridae family and Przondovirus genus, was identified. It rapidly lyses K. pneumoniae (K20 serotype), inhibits biofilm formation, and exhibits a burst size of 37.4 plaque-forming units/cell. The phage is stable at temperatures ranging from 0°C to 40°C and pH values between 6 and 9. Its genome, 41,155 bp in length, contains 46 coding sequences. The phage has no genes associated with antibiotic resistance, virulence, or lysogeny. In vivo , PK2420 substantially reduced K. pneumoniae bacterial loads, improved survival rates, and alleviated pneumonia severity without observable side effects. Phage PK2420 exhibits lytic activity against K. pneumoniae both in vitro and in murine models, providing a promising and safe option for the treatment of hvKp infections. IMPORTANCE Our investigation provides insights into the interaction mechanism among hypervirulent Klebsiella pneumoniae (hvKp) (K20 serotype), phage, and the host in a mouse pneumonia model, offering a valuable reference for future research on phage pharmacokinetics. This study demonstrated that bacteriophage PK2420 exhibits promising biosafety and therapeutic efficacy against hvKp-induced pulmonary infections and dissemination in a murine model. These findings suggest that phage PK2420 may be a potential option for the clinical treatment of hvKp infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Capital Institute of Pediatrics-Peking University Teaching Hospital, Beijing, China.
- Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China.
- Children's Hospital Capital Institute of Pediatrics, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
ORCID-Profile: Jinfeng Chen, Lin Gan, Jing Yuan
Förderung
- Natural Science Foundation of Beijing Municipality
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes
- National Natural Science Foundation of China
- Capital Health Research and Development of Special Fund
- Beijing High-Level Public Health Technical Talent Project
- Beijing Hospitals Authority's Ascent Plan
Zitieren
APA
Chen, J., Feng, J., Cui, X., Huang, L., Du, B., Xia, Y., Xue, G., Feng, Y., Ke, Y., Zhao, H., Cui, J., Yan, C., Gan, L., Fan, Z., Fu, T., Xu, Z., Yang, Y., Yu, Z., Zhao, S., …, & Yuan, J. (2025). Genomic analysis and therapeutic efficacy evaluation of bacteriophage PK2420 for pneumonia caused by hypervirulent Klebsiella pneumoniae (K20 serotype). mSystems. https://doi.org/10.1128/msystems.01632-24
Vancouver
Chen J, Feng J, Cui X, Huang L, Du B, Xia Y, et al. Genomic analysis and therapeutic efficacy evaluation of bacteriophage PK2420 for pneumonia caused by hypervirulent Klebsiella pneumoniae (K20 serotype). mSystems. 2025. doi:10.1128/msystems.01632-24
BibTeX
@article{Chen2025,
author = {Chen, Jinfeng and Feng, Junxia and Cui, Xiaohu and Huang, Lijuan and Du, Bing and Xia, Yuyan and Xue, Guanhua and Feng, Yanling and Ke, Yuehua and Zhao, Hanqing and Cui, Jinghua and Yan, Chao and Gan, Lin and Fan, Zheng and Fu, Tongtong and Xu, Ziying and Yang, Yang and Yu, Zihui and Zhao, Shuo and Wang, Zhen and Kong, Yiming and Jiang, Boyi and Wang, Mingxuan and Ling, Mengyao and Yuan, Jing},
title = {Genomic analysis and therapeutic efficacy evaluation of bacteriophage PK2420 for pneumonia caused by hypervirulent Klebsiella pneumoniae (K20 serotype)},
journal = {mSystems},
year = {2025},
doi = {10.1128/msystems.01632-24}
}
EUVIMED